Speedy US approval for Novartis’ Tabrecta
The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option
Read More
Tag: FoundationOneCDx
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
